Charles Ross Carter - 28 Jun 2024 Form 4 Insider Report for CERO THERAPEUTICS HOLDINGS, INC. (CERO)

Reporting relationship: Chief Financial Officer
Issuer ticker: CERO
Reported as of: 28 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Jul 2024, 16:01:02 UTC
Prior SEC filing: 27 Mar 2024
Next SEC filing: 08 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Charles Carter

Key filing fact

Charles Ross Carter filed Form 4 for CERO THERAPEUTICS HOLDINGS, INC. (CERO) on 01 Jul 2024.

Key facts

This page summarizes Charles Ross Carter's Form 4 filing for CERO THERAPEUTICS HOLDINGS, INC. (CERO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 Jul 2024, 16:01.

Change

Previous filing in this sequence was filed on 27 Mar 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CERO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +100,000
Change %
Price: $0.000000
Shares after: 100,000
Date: 28 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $0.3000
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

All of the shares underlying this option will vest on the date of the acceptance of an Investigational New Drug application by the U.S. Food and Drug Administration, subject to the Reporting Person's continued service on such vesting date.